Skip to main content
. Author manuscript; available in PMC: 2011 Jun 20.
Published in final edited form as: Neuroscience. 2005;132(4):1017–1026. doi: 10.1016/j.neuroscience.2005.01.041

Fig. 6.

Fig. 6

Graphs showing the time course of the effects of i.c.v. or i.t. combined administration of MK-801 (1.8 μg) and (LY215490 (0.03 μg; n=5 for each treatment group), on the bladder contraction amplitude ((a) for i.c.v. and (c) for i.t.) and EUS EMG activity ((b) for i.c.v. and (d) for i.t.) during continuous filling (0.21 ml/min) CMGs. Opened, and closed arrowheads indicate (i.c.v. or i.t.) injection of vehicle (artificial CSF only) or MK-801 (1.8 μg), and LY215490 (0.03 μg), respectively. Abscissa, time scale (min). Ordinates, bladder contraction amplitude (% of control; a, c) or EUS EMG activity (% of control; b, d).